White Paper: Medicare and Commercial Plans Fail to Get New Generics to Patients
Part D Design Increases Patient Out-of-Pocket Costs Although public polling continues to find high drug costs are a major concern for voters, health plans in the Medicare program and the commercial market are delaying patient access to new lower-priced generic competitors.1 Download White Paper New generic competitors to high-priced brand drugs are particularly important for […]
Insurers Fail to Get New Generics to America’s Patients
WASHINGTON, DC (February 20, 2020) — “America looks to new generic drugs for significant savings on medicine, but our newest data show Medicare and commercial health plans delay their coverage. Delayed competition from generics increases costs for patients, taxpayers and employers and rewards the makers of high-priced brand-name drugs. Federal and state policymakers must act […]
Seniors Denied Access to New, Lower-Priced Generic Drugs Due to Medicare Coverage Delays
AAM Analysis Shows Patients Wait Up to Three Years for First Generic Competitors to Costly Brands WASHINGTON, DC (September 19, 2019) – The Association for Accessible Medicines (AAM) today released a white paper, “Access Denied: Why New Generics Are Not Reaching America’s Seniors.” It highlights striking new data on the treatment of generic medicines in […]
AAM Response to CMS Final 2020 Call Letter
Association for Accessible Medicines Statement Responding to the CMS Calendar Year (CY) 2020 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter WASHINGTON, DC (April 1, 2019) – We commend the Administration for encouraging Part D sponsors to prioritize formulary placement for generics and biosimilars and for recognizing situations […]
AAM Statement in Response to Administration’s FY 2020 Budget Proposal
WASHINGTON, DC (March 11, 2019) –The Association for Accessible Medicines commends the Administration’s efforts to reduce out-of-pocket costs and overall drug spending. However, the proposal to amend the 180-day period of exclusivity for first generics would only weaken this critical incentive for competition and ensure that more non-innovative brand-name drug patents remain in place, delaying […]
AAM Statement on Avalere Medicare Analysis
AAM Statement on Generic Drugs in Medicare Part D. Trends in Tier Structure and Placement, Avalere Health, May 22, 2018: “In 2015, patients spent more than $6 billion in additional out-of-pocket costs on generic drugs compared to 2011. These increased out-of-pocket expenses on low-cost generics are being used by the plans to mask increases in […]
Seema Verma Approved as CMS Administrator – Let’s Preserve and Strengthen Medicare and Medicaid Savings
Statement of Chester “Chip” Davis Jr., President and CEO of the Association for Accessible Medicines on the Confirmation of Seema Verma as Administrator of the Centers for Medicare and Medicaid Services: WASHINGTON, DC (March 13, 2017) – “We congratulate Seema Verma on her confirmation by the U.S. Senate to be the next Administrator of the […]
